Get checked 

Public Health & Cancer Awareness

Each month, the UVM Cancer Center shares messages related to a cancer-specific health observance.

FEBRUARY: CANCER PREVENTION MONTH

Experts believe that up to 50% of cancers can be prevented. That’s because certain daily habits can make us more likely to get cancer. Changing these habits may help prevent cancer.

5 lifestyle changes that may reduce your cancer risk:

  • Quit smoking (802quits.org is Vermont's tobacco cessation resource. ). 
  • Make healthy food choices.
  • Get regular checkups & screenings.
  • Stay active.
  • Protect your skin with sun safe behaviors.

LEARN MORE

 

MARCH: COLORECTAL CANCER AWARENESS MONTH

March is colorectal cancer awareness month. With regular screening, almost all colorectal cancer can be prevented. If you are 45 or older, please talk to your doctor about screening options. 

VIEW RESOURCES

 

 

MAY: SKIN CANCER AWARENESS MONTH

Did you know that Vermont has the second highest incident rate of melanoma in the U.S.?
May is skin cancer awareness month and by limiting sun exposure you can reduce your skin cancer risk.
Three Prevention Tips:

  1. Cover up. Wear wide-brimmed hats, sun-protective clothing and sunglasses.
  2. Stay indoors between 10 a.m. and 2 p.m. or seek shade.
  3. Wear sunscreen, with a sun protection factor (SPF) of 30 or higher.

Early detection promotes successful treatment, talk to your doctor about your screening options. 

Summer Safety Tips: Find some simple health and safety tips for summertime activities.

Something New Under The Sun: Learn about the signs of melanoma.

9 Things I'd Never Do As A Dermatologist: Summer's coming. How many of these ski 'don'ts' do you do?

 

SEPTEMBER: PROSTATE CANCER AWARENESS MONTH

Prostate cancer is the second most common type of cancer. UVM Cancer Center clinical member, Shahid Ahmed, MD, MBBS, a medical oncologist specializes in cancers of the urinary system and the reproductive organs in men and provides an overview of diagnosis and tips to manage treatment side effects in this Healthsource article. 

READ ARTICLE

 

OCTOBER: BREAST CANCER AWARENESS MONTH

25th Annual Women's Health and Cancer Conference: View recordings of presentations and panels about surgical options, survivorship, integrative care, palliative care, and breakthrough advances in the research.

Breast Cancer Portfolio: Learn more about the UVM Cancer Center's research, education, community outreach, and clinical care related to breast cancer.

Clinical Trials: See what clinical trials are being offered related to breast cancer.

Genetic Testing for Cancer and Risk Assessment: Learn about the team of clinicians who provide genetic screening and risk assessment.

Screening Guidelines: The American Cancer Society recommends these screening guidelines. 

Breast Cancer Screening: Reach out to your primary care provider or the Breast Care Center if you are due for a screening.

Support Services: There are many resources for patients in treatment or patients who have completed their treatment, including support groups and the popular Steps to Wellness class. 

 

NOVEMBER: LUNG CANCER AWARENESS MONTH

Lung Cancer Public Health Campaign. The UVM Cancer Center teamed up with Dartmouth Cancer Center and Vermonters Taking Action Against Cancer to encourage more Vermonters to get screened for lung cancer. When detected early, local tumors can be removed which increases the patient's survival rate from 24% to 60%.

Learn more about:

  • Guidelines
  • Screening locations in Vermont
  • Eligibility requirements

VIEW CAMPAIGN

Lung Cancer Research. Learn more about the Cunniff lab's promising new therapy for mesothelioma and metastatic cancer, which is currently a Phase I clinical trial. 

Clinical Trials: See what clinical trials are being offered related to lung cancer.

Clinical Trials Awareness Day

May 21, 2024 by Jeff Wakefield

The UVM Medical Center is an academic partner to the UVM Cancer Center

Goal Is to Educate Public on Benefits of Clinical Trials, Counter Misinformation like “Placebo Myth,” Encourage Participation

            Surgery to remove malignant melanoma, the deadliest form of skin cancer, is often life-saving. But cutting away both the melanoma and up to four centimeters of the skin around it, which could harbor cancer cells, may cause long-term pain and scarring in patients. 

            A clinical trial at the UVM Cancer Center, currently enrolling volunteers, asks the question: Would reducing the amount of skin removed around the melanoma improve patients’ post-surgery quality of life without increasing the risk of melanoma returning? 

Raising Awareness of Clinical Trials 

            The trial, led by Jessica A. Cintolo-Gonzalez, MD, is one of more than 100 the UVM Cancer Center is currently conducting and is especially relevant in Vermont, which has the second highest incident rate of melanoma in the United States. 

            The Association of Clinical Trial Research Professionals has designated May 20 Clinical Trials Awareness Day, designed to raise public awareness of the benefits of clinical trials like the melanoma study, counter misinformation, and encourage more eligible patients to enroll. 

            Dr. Randall Holcombe, MD, MBA, director of the UVM Cancer Center, is bullish on the benefits clinical trials can bring to cancer patients. 

            A well-designed clinical trial, like those offered by UVM, is almost universally the best option for treating cancer, he says, potentially more effective and less toxic than the current standard of care.

             “I tell my patients that the treatment they're getting today was a clinical trial 10 years ago, and the clinical trial that they participate in today has the potential of setting a new standard of care 10 years from now,” he said. 

The placebo myth

            Holcombe says patients who decide not to enroll in a clinical trial are often swayed by a common misconception. Many believe they’ll either be given an experimental new treatment or, via a placebo, no treatment at all. 

              But giving a sick patient a placebo — essentially letting their disease progress — is unethical, Holcombe said and doesn’t happen in tests of new treatments.

            Instead, the new treatment is often compared with the standard of care, that patients would normally be receiving if not participating in a trial. “You really can’t lose,” Holcombe said.

“Less than 5% of adult patients diagnosed with cancer participate in clinical trials. However, in most instances, patients are monitored more closely than when receiving standard-of-care treatment. Many patients who have participated in a clinical trial have positive things to say.” Said Christa Varnadoe-Rothman, DNP, AGNP-C, OCN, CCRP.  

Further, the Coalition of Cancer Cooperative Groups (2009) found that of those who participated in clinical trials: 91% would recommend a trial to others, 92% had a positive experience, and 96% felt that they were treated with dignity and respect. (See below for five common myths about clinical trials).  As well as helping themselves, patients in clinical trials are helping researchers develop the therapies of the future that could help many others. 

            As well as helping themselves, patients in clinical trials are helping researchers develop the therapies of the future that could help many others. 

            “If you look at the history of clinical research over the last 30 years, you'll find that about a third to half the time, clinical trials have moved the bar and established a new standard of care,” Holcombe said. “This is how we make continual progress against difficult diseases like cancer.”

First Clinical Trial — in 1774

            Clinical Trials Day is celebrated globally each May 20 to recognize the day in 1774 that James Lind, a ship’s surgeon in the British Royal Navy, started what is often considered to be the first randomized clinical trial. In this case, it was to study the effects of different treatments on scurvy, a disease caused by a deficiency of vitamin C, and a major scourge for sailors on long voyages. 

Five Myths About Clinical Trials and Cancer

Myth #1: Patients frequently get placebos.  
Fact: Placebos are very rarely used on clinical trials for cancer patients and every patient gets at least the standard of care. 

Myth #2: Patients who enroll in a clinical trial for cancer are locked in and won’t be able to change treatments. 
Fact: Clinical trial participants can choose to stop participating at any time and return to their standard quality of care. 

Myth #3: Clinical trials are just for patients with advanced stages of cancer when no other option is possible.
Fact: Clinical trials provide the very highest level of care for patients at all stages of cancer. 

Myth #4: Patients in clinical trials are often treated like guinea pigs.
Fact: There are strict rules about how patients are consented and monitored. Patients’ safety and providing the highest quality of care are always top priorities. 

Myth #5: Clinical trials for cancer are dangerous because they use new medicines. 
Fact: While there is some level of risk, clinical trial drugs go through rigorous testing for safety in humans, and patients are monitored closely for adverse effects.  


More information: clinical trials at the UVM Cancer Center.
UVM Cancer Center Director, Randall Holcombe, MD, MBA speaks to WCAX on Clinical Trials Awareness Day.